- Home
- HKIT vs NRXS Comparison
HKIT vs NRXS Comparison
Compare HKIT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HKIT | NRXS |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7M | 46.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HKIT | NRXS |
|---|---|---|
| Price | $1.99 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 40.1K | ★ 83.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $146.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $1.33 |
| 52 Week High | $4.18 | $6.20 |
Technical Indicators
Market Signals| Indicator | HKIT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 69.91 |
| Support Level | $1.96 | $4.50 |
| Resistance Level | $2.20 | $4.50 |
| Average True Range (ATR) | 0.12 | 0.38 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 47.06 | 92.49 |
Price Performance
Historical ComparisonAbout HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).